ETF Holdings Breakdown of AVIR

AVIR institutional holdings

The adjusted close for AVIR on 2025-11-11 was 3.38

The following institutional investment holdings of AVIR have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	53,894	USD 182,162 1.5%	3.38
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	53,894	USD 182,162 1.5%	3.38
Total =		107,788	USD 364,324

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with AVIR

Atea Pharmaceuticals (NASDAQ:AVIR) Rating Lowered to “Sell” at Wall Street Zen

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday. Separately, Morgan Stanley decreased their price objective on Atea Pharmaceuticals from $6.20 to $6.00 and set an “equal weight” rating on the stock […] - 2025-08-11 03:58:51

Two Sigma Advisers LP Sells 88,800 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Two Sigma Advisers LP lessened its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 15.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 493,600 shares of the company’s stock after selling 88,800 shares during the period. Two Sigma Advisers LP’s holdings in Atea Pharmaceuticals were worth $1,654,000 at the end of […] - 2025-05-30 05:34:49

96,433 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets acquired a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 96,433 shares of the company’s stock, valued at approximately $323,000. Several other institutional investors also recently bought and sold shares […] - 2025-05-27 04:38:55

Graham Capital Management L.P. Buys Shares of 12,511 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Graham Capital Management L.P. bought a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,511 shares of the company’s stock, valued at approximately $42,000. A number of other hedge […] - 2025-05-20 05:09:23

Dimensional Fund Advisors LP Increases Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Dimensional Fund Advisors LP lifted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 23.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 977,470 shares of the company’s stock after purchasing an additional 183,844 shares during the period. Dimensional Fund Advisors LP’s holdings […] - 2025-05-14 04:36:48

Barclays PLC Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Barclays PLC lifted its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 13.0% in the fourth quarter, HoldingsChannel reports. The firm owned 200,113 shares of the company’s stock after purchasing an additional 23,036 shares during the quarter. Barclays PLC’s holdings in Atea Pharmaceuticals were worth $671,000 at the end of the most recent […] - 2025-05-08 04:36:45

Marshall Wace LLP Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Marshall Wace LLP purchased a new position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 77,581 shares of the company’s stock, valued at approximately $260,000. A number of other hedge funds also recently bought and sold shares of the stock. Barclays PLC increased its […] - 2025-05-05 05:05:05

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Position Raised by Federated Hermes Inc.

Federated Hermes Inc. boosted its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 1.9% during the 4th quarter, HoldingsChannel reports. The firm owned 582,939 shares of the company’s stock after buying an additional 10,856 shares during the quarter. Federated Hermes Inc.’s holdings in Atea Pharmaceuticals were worth $1,953,000 at the end […] - 2025-04-14 05:15:06

Back to Listing

Disclaimer